Cadmium-Induced Effects on Bone in a Population-Based Study of Women

Agneta Åkesson,1 Per Bjellerup,2 Thomas Lundh,3 Jonas Lidfeldt,4 Christina Nerbrand,5 Göran Samsoe,6 Staffan Skerfving,3 and Marie Vahter1

1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 2Department of Clinical Chemistry, Karolinska University Hospital, Huddinge, Sweden; 3Department of Occupational and Environmental Medicine, University Hospital, Lund, Sweden; 4Department of Community Health, Malmö University Hospital, Malmö, Sweden; 5Department of Medicine, and 6Department of Gynecology and Obstetrics, University Hospital, Lund, Sweden

High cadmium exposure is known to cause bone damage, but the association between low-level cadmium exposure and osteoporosis remains to be clarified. Using a population-based women’s health survey in southern Sweden (Women’s Health in the Lund Area (WHHLA)) with no known historical cadmium contamination, we investigated cadmium-related effects on bone in 820 women (53–64 years of age). We measured cadmium in blood and urine and lead in blood, an array of markers of bone metabolism, and forearm bone mineral density (BMD). Associations were evaluated in multiple linear regression analysis including information on the possible confounders or effect modifiers: weight, menopausal status, use of hormone replacement therapy, age at menarche, alcohol consumption, smoking history, and physical activity. Median urinary cadmium was 0.52 μg/L adjusted to density (0.67 μg/g creatinine). After multivariate adjustment, BMD, parathyroid hormone, and urinary deoxypyridinoline (U-DPD) were adversely associated with concentrations of urinary cadmium (p < 0.05) in all subjects. These associations persisted in the group of never-smokers, which had the lowest cadmium exposure (mainly dietary). For U-DPD, there was a significant interaction between cadmium and menopause (p = 0.022). Our results suggest negative effects of low-level cadmium exposure on bone, possibly exerted via increased bone resorption, which seemed to be intensified after menopause. Based on the prevalence of osteoporosis and the low level of exposure, the observed effects, although slight, should be considered as early signals of potentially more adverse health effects. Key words: biochemical bone markers, bone mineral density, cadmium, lead, osteoporosis, women. Environ Health Perspect 114:830–834 (2006). doi:10.1289/ehp.8763 available via [Online 2 February 2006]

Osteoporosis is characterized by low bone mass and microarchitectural deterioration of the skeleton, leading to fragility and increased risk of fractures (Consensus Development Conference 1993). Sweden is among the countries with the highest incidence of osteoporotic fractures (Ismail et al. 2002; Kanis et al. 2002), but established risk factors cannot fully explain the wide geographic differences and the increased incidence over time. Identification of risk factors is vital to prevent reduction of life quality and life expectancy and to minimize the high costs of treatment associated with the disease. Known predictors of low bone mass are older age, female sex, family history of osteoporosis, early menopause, physical inactivity, low body weight, low intake of calcium and vitamin D, smoking, and alcohol consumption (Genant et al. 1999; National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001).

The toxic effect of cadmium on bone became evident at the outbreak of Itai-itai disease in Japan, where severe renal and skeletal damage in women was associated with consumption of heavily cadmium-polluted rice (Kjellström 1992). Cadmium is a widespread environmental pollutant, present in food (mainly cereals, vegetables, and shellfish) and tobacco. It poses a threat to human health because of its long retention (decades) in the kidneys (Järup et al. 1998). Recent studies indicate that relatively low exposure may also affect the skeleton (Alvén et al. 2004; Staessen et al. 1999), but the relationship is not well documented. Whether the effects are mediated directly on bone or are secondary to kidney damage is still unclear (Kjellström 1992).

In contrast to cadmium, lead accumulates in bone by the replacement of calcium, and the skeleton contains as much as 90% of the lead body burden (Berglund et al. 2000; Nilsson et al. 1991).

The aim of this study was to assess associations between cadmium retention and bone effects in women of upper middle age, the most susceptible part of the population, with regard to both cadmium retention (Nishijo et al. 2004) and osteoporosis (Ismail et al. 2002; Kanis et al. 2002). We examined indicators of bone status, reflecting both short-term effects [markers of bone metabolism and parathyroid hormone (PTH)] and long-term effects [bone mineral density (BMD)]. We addressed the question of whether the effects of cadmium are mediated through kidney damage. We also assessed the impact of bone remodeling on endogenous lead exposure.

Materials and Methods

Study population. The Women’s Health in the Lund Area (WHHLA) study, a population-based study of all women 50–59 years of age in the community of Lund, in southern Sweden (n = 10,766), started in December 1995 (Lidfeldt et al. 2001). In June 1999, when 1,160 subjects remained to be examined, the study was extended to include health aspects of cadmium and lead (Åkesson et al. 2005). The participation rate was 71% (n = 820). The exclusion criteria were hypo- and hyperparathyroidism (n = 4), rheumatoid arthritis (n = 7), or oral use of corticosteroid drugs (n = 6). We collected data on lifetime smoking, alcohol consumption, physical activity, and reproductive factors, including hormone replacement therapy (HRT), via a questionnaire. Body weight and height were measured. We obtained morning spot urine from 797 women and blood from 727 women. All samples were collected during 8 months from June 1999 through January 2000. The ethics committee at Lund University approved the WHHLA study, and oral informed consent was obtained from each participant.

Measurements. Exposure assessment was based on cadmium in blood as a measure of ongoing exposure (which we assume has been fairly constant over time) and cadmium in urine as a measure of body burden (cadmium in urine correlates well with cadmium in the kidney cortex; Järup et al. 1998; Orlowski et al. 1998). In addition, we measured lead in blood (indicator of exposure). All equipment used in the study was tested, and possible contamination was below the limit of detection.

Address correspondence to A. Åkesson, Division of Metals and Health, Institute of Environmental Medicine, Karolinska Institutet, Box 210, 171 77 Stockholm, Sweden. Telephone: 46-8-524-875-42. Fax: 46-8-33-70-39. E-mail: agneta.akesson@imm.ki.se

We thank U. Strömberg for statistical advice. We also thank the late A. Schütz, H. Ottosson, A. Akantis, A.-M. Åberg, and B. Erdling.

Funding was provided by the Swedish Research Council/Medicine; the Medical Faculty of Lund University; Karolinska Institutet; the National Swedish Environmental Protection Agency; the Swedish Foundation for Strategic and Environmental Research; the Swedish Society of Medicine; Primary Care, and R&D, County Council of Skåne; the Swedish Research Council for Environment, Agricultural Sciences, and Spatial Planning; and the Swedish Council for Working Life and Social Research.

The authors declare they have no competing financial interests.

Received 21 October 2005; accepted 2 February 2006.
(LOD). Blood cadmium [LOD = 0.12 μg/L; precision = coefficient of variation (CV) = 7.4%], blood lead (LOD = 0.26 μg/L; CV = 3.1%), urinary cadmium (LOD = 0.31 μg/L; CV = 8.5%), and urinary calcium (LOD = 1.6 mg/L; CV = 6.4%) were determined by inductively coupled plasma mass spectrometry (Barany et al. 1997). The analytical accuracy was good and is described in detail elsewhere (Åkesson et al. 2005).

We measured the following biochemical markers related to bone metabolism: PTH, osteocalcin, and bone alkaline phosphatase (bALP) in serum; and deoxypyridinoline (U-DPD) and calcium in urine. We used immunoassays to determine intact PTH (Elecsys; Roche, Mannheim, Germany), osteocalcin (ELSA-Osteo; CIS Bio International, Gif-Sur-Yvette Cedex, France), and U-DPD (Immulite 2000 Pyrilinks-D; DPC, Los Angeles, CA, USA) and immunoradiometric assay to detect bALP (Tandem-R Ostase; Beckman Coulter, Inc., Fullerton, CA, USA). The CVs were < 4% for PTH, 10% for osteocalcin, < 9% for U-DPD, and < 11% for bALP.

We measured BMD of the nondominant wrist (at the 8 mm distal position) using dual-energy X-ray absorptiometry (DXT 200; Osteometer MediTech, Inc., Hawthorne, CA, USA). We used a phantom for daily calibration of the instrument, and one technician performed all measurements. The measured BMD was automatically compared with a “reference” population furnished by the instrument supplier, giving T-scores, defined as (BMD − BMDref)/SD, where BMDref is the obtained BMD, BMDref is the mean value for 20-year-old Danish female controls, and SD is the standard deviation in the same reference population. Osteopenia was defined as −2.5 < T-score < −1.0, and osteoporosis as T-score < −2.5, according to the World Health Organization (WHO), based on the measurement of proximal femur (WHO 1994).

The kidney-effect markers measured were estimated glomerular filtration rate (GFR), creatinine clearance, and human-complex-forming protein (protein HC), and N-acetyl-β-d-glucosaminidase (U-NAG) in urine, as described previously (Åkesson et al. 2005).

Because creatinine excretion is dependent on muscle mass, which in turn may predict BMD, we chose to adjust all urinary markers to the group mean urinary density (1.015 g/mL) instead of to urinary creatinine (Åkesson et al. 2005; Suwazono et al. 2005).

Statistical analyses. Data from two independent groups of subjects were compared by the Mann-Whitney U-test. We used Spearman rank correlation (r) or Kendall’s tau to assess univariate associations (p ≤ 0.1). In multiple linear regression models, each bone-related variable was evaluated in relation to cadmium, potential confounders (factors associated with both cadmium and bone) and effect modifiers (factors associated with bone). We explored possible interactions in the model. Because the season of sampling correlated with blood and urinary cadmium, BMD, PTH, U-DPD, and urinary calcium, it was included in the models. Residual and goodness-of-fit analyses indicated no deviation from a linear pattern in the regression models. The final regression model included, apart from cadmium, only statistically significant variables (p ≤ 0.05). All tests were two sided, and statistical evaluation was performed using SPSS (version 12.01; SPSS Inc., Chicago, IL, USA).

Results

The main characteristics of the participants are shown in Table 1. Current smokers had, on average, cadmium concentrations three times as high in blood (1.1 vs. 0.30 μg/L) and 1.5 times as high in urine (0.76 vs. 0.45 μg/L) compared with never-smokers.

In a first evaluation, we assessed the univariate associations between cadmium and the various bone-related variables and covariates (Table 2). Urinary cadmium was negatively associated with BMD (Table 2, Figure 1) and PTH, and positively associated with bALP and U-DPD (Table 2, Figure 2), but not with osteocalcin or urinary calcium. Similar but less pronounced associations were obtained for blood cadmium. Physical activity, parity, and total months of lactation were not associated with the bone-related variables.

Table 1. Participant characteristics and data on exposure and bone-related variables in a population-based study of Swedish women.

| Population characteristics | Median (5th–95th percentiles) | No. of samples |
|-----------------------------|-------------------------------|---------------|
| Age (years)                 | 58 (54–63)                    | 804           |
| Weight (kg)                 | 69 (54–94)                    |               |
| Living alone or with children (%) | 17                           |               |
| Education > 12 years (%)    | 27                            |               |
| Smokers: never/former/current (%) | 55/24/22                   |               |
| Pack-years: former/current smokers | 10 (1–36)/20 (4–42) |               |
| Alcohol consumption (grams ethanol/week) | 20 (0–150)               |               |
| Menarche (age)              | 13 (11–16)                    |               |
| Parity                      | 2 (0–4)                       |               |
| Lactation (months)          | 6 (0–24)                      |               |
| Prenatal/postmenopause (%)  | 3/5/62                        |               |
| Exposure variables          |                               |               |
| Blood cadmium (μg/L)        | 0.38 (0.16–1.8)               | 715           |
| Urinary cadmium (μg/L)      | 0.52 (0.24–1.3)               | 795           |
| Blood lead (μg/L)           | 22 (11–46)                    | 716           |
| Bone-related variables      |                               |               |
| BMD (g/cm²)                 | 0.44 (0.33–0.54)              | 803           |
| Osteopenia, −2.5 < T-score < −1.0 (%) | 42                          |               |
| Osteoporosis, T-score < −2.5 (%) | 7.2                         |               |
| PTH (ng/L)                  | 28 (13–57)                    | 719           |
| Osteocalcin (µg/L)          | 19 (9–33)                     | 719           |
| bALP (µg/L)                 | 12 (6–21)                     | 645           |
| U-DPD (nmol/L)              | 46 (25–85)                    | 794           |
| Urinary calcium (mg/L)      | 135 (57–265)                  | 797           |

Data are presented as median (5–95th percentiles) except as noted.

*Adjusted to mean density of 1.015 g/mL.

Women on HRT had significantly higher BMD (p < 0.001) as well as lower osteocalcin, bALP, U-DPD, blood lead (p < 0.001), and urinary calcium (p < 0.023) than postmenopausal women without HRT. There were no differences in blood or urinary cadmium between the two groups.

Multivariate analyses. In the multiple linear regression analyses, we evaluated further the associations between cadmium and bone by including potential confounders and effect modifiers (e.g., smoking and body weight, age, alcohol consumption, menopausal status including HRT, and age at menarche) (Table 3). We did not include blood lead as an explanatory variable in the models, in spite of the fact that it was associated with several of the skeletal biomarkers and BMD, because there is a known inverse relationship, that is, that skeletal demineralization releases lead into the blood. In the adjusted model, urinary cadmium, but not blood cadmium, showed a significant negative association (p = 0.047) with BMD. In a separate analysis in never-smokers with a lower cadmium exposure, the corresponding result was β = −0.02 g/cm² per microgram per liter (p = 0.045; data not shown). Based on the adjusted model, we calculated the differences in BMD for the average woman with respect to age and weight at different levels of exposure. The exposure corresponding to the 99th percentile of urinary cadmium concentration had, on average, 5–6% lower BMD than those in the first percentile. This magnitude of difference was
similar to that observed by a 6-year increase in age or an 11-kg lower body weight.

Both blood and urinary cadmium were negatively associated with PTH (Table 3); this was true for urinary cadmium even after excluding ever-smokers (β = −5.4 ng/L per microgram per liter; p = 0.027; data not shown). Urinary cadmium, but not blood cadmium, displayed a near-significant association (p = 0.06) with bALP. Further, urinary cadmium was associated with U-DPD (Table 3), even in never-smokers (β = 16 nmol/L per microgram per liter; p < 0.001; data not shown). The association between U-DPD and urinary cadmium was more pronounced (interaction term; p = 0.022) in postmenopausal women (β = 21 nmol/L per microgram per liter; Table 3) than in the HRT group together with premenopausal women (β = 12 nmol/L per microgram per liter).

In additional analyses, we evaluated the link between the cadmium-associated bone markers and the kidney effect markers. We included each kidney-effect marker in the multiple linear regression models for BMD, PTH, and U-DPD. Both urinary cadmium and U-NAG were associated with PTH and U-DPD but not with BMD. However, GFR and urinary protein HC were not associated with any of the cadmium-associated bone markers.

Blood lead was higher in the postmenopausal women without HRT than in the HRT group and was associated with all bone parameters, except PTH (Table 2, Figure 3). Potential confounders were smoking and alcohol intake. Body weight and HRT were also associated with both blood lead and bone effects markers but are likely to be steps on a causal route rather than confounders. When body weight and alcohol were included in a multivariate model, significant associations with blood lead were still present for osteocalcin, bALP, U-DPD, and urinary calcium (all p-values ≤ 0.037). However, when HRT was included, the associations with blood lead became weaker (bALP and urinary calcium were no longer statistically significant, and the slopes decreased for osteocalcin and U-DPD).

**Discussion**

This population-based study of upper-middle-age women, representative of the general population of southern Sweden, is the first to report assessment of a variety of biochemical bone markers in relation to cadmium exposure. We showed clear associations between increasing cadmium body burden, on one hand, and decreasing BMD, increasing bone resorption (U-DPD), and decreasing PTH, on the other. The associations persisted even in the group of never-smokers, which had the lowest cadmium exposure.

This study has several methodologic advantages, including the large sample size and high participation rate. Nevertheless, in health surveys, there may be a selection such that subjects with diseases, probably including those with bone disorders, participate to a lesser or to a greater extent than others. If fewer subjects with diseases participate, we may underestimate the risk of cadmium-induced bone damage; if more of these subjects participate, it may affect the generalizability of the results. However, the present prevalence of osteoporosis agrees well with the 7% value previously reported in Swedish women of the same age (Ringertz et al. 1995). Other advantages are the inclusion of several different markers of bone effects and confounders, and the fact that each individual’s exposure has been assessed separately, with good analytical accuracy. Any analytical imprecision would have caused a bias toward the null.

Urinary spot samples must be adjusted for dilution. This is frequently done by adjusting to urinary creatinine, but this method may introduce bias because it is dependent on muscle mass and thus affected by age and physical fitness (Suwazono et al. 2005), which are also predictors of bone status. In fact, creatinine-adjusted urinary cadmium displayed an even more pronounced statistically significant association with BMD. In view of this possible bias, we chose to correct by density (Åkesson et al. 2005; Suwazono et al. 2005). However, the choice is not obvious, especially not in a population as homogeneous for sex and age as that examined in the present study.

The cross-sectional study design precludes definite conclusions as to the direction of causality. The bone markers also showed clear associations with blood lead. Considering that about 90% of all the body burden of lead is localized to bone, even a minor increase of skeletal turnover, as in menopause, would

---

**Table 2. Associations between exposure and bone-related variables (Spearman rank correlation coefficients).**

| Blood cadmium | Urinary cadmium | Blood lead | Menarche | Pack-years of smoking | Alcohol | Weight | BMD     | PTH     | Osteocalcin | bALP | U-DPD | Urinary calcium |
|---------------|-----------------|------------|----------|-----------------------|---------|--------|---------|---------|-------------|------|-------|----------------|
| Age           | −0.02           | −0.03      | −0.04    | 0.09*                 | −0.07†  | −0.15**| 0.06†   | −0.18** | 0.03        | 0.06 | 0.08* | −0.02         | −0.04 |
| Menarche      | 0.05            | 0.04       | 0.08*    | 0.09*                 | −0.07†  | −0.15**| 0.06†   | −0.18** | 0.03        | 0.06 | 0.08* | −0.02         | −0.04 |
| Pack-years    | 0.57**          | 0.41**     | 0.19**   | 0                   | 0       | 0      | 0       | 0       | 0           | 0    | 0     | 0              | 0     |
| Smoking       | −0.01           | 0.02       | 0.36**   | 0.02                 | 0.10*   | 0.04   | 0.01    | 0.35**   | 0.10**      | 0.10** | 0.10** | 0.10**        | 0.10** |
| Weight        | −0.11**         | −0.15**    | −0.07†   | −0.12**              | −0.07*  | −0.08* | 0.01    | 0.11*    | 0.11*        | 0.11* | 0.11* | 0.11*         | 0.11* |
| U-DPD         | −0.08*          | −0.12**    | −0.07†   | −0.07*               | −0.04   | 0.01   | 0.35**   | 0.17**   | 0.17**      | 0.17** | 0.17** | 0.17**        | 0.17** |
| Osteocalcin   | −0.03           | 0.05       | 0.23**   | 0.04                 | 0.05    | 0.05   | 0.24**   | 0.16**   | 0.16**      | 0.16** | 0.16** | 0.16**        | 0.16** |
| bALP          | 0.02            | 0.08*      | 0.17**   | 0.05                 | 0.09*   | 0.09*  | 0.24**   | 0.25**   | 0.25**      | 0.25** | 0.25** | 0.25**        | 0.25** |
| U-DPD         | 0.07†           | 0.27**     | 0.11*    | 0.04                 | −0.07*  | 0.05   | 0.06    | 0.25**   | 0.25**      | 0.25** | 0.25** | 0.25**        | 0.25** |
| Urinary calcium| −0.02           | 0.01       | 0.12     | −0.01               | 0.03    | −0.03 | −0.12**  | −0.11*   | 0.17**      | 0.16** | 0.16** | 0.16**        | 0.16** |

NR, not relevant.

*0.05 < p ≤ 0.10. **0.001 < p ≤ 0.05. ***p ≤ 0.001.
Affect the levels of lead in blood. Interestingly, the inclusion of HRT in the models decreased the strength of these associations, which indicates an effect of menopause and a protective effect of estrogen therapy, as previously shown (Garrido Latorre et al. 2003; Korrick et al. 2002; Nash et al. 2004; Vaher et al. 2004; Webber et al. 1995). Because the skeleton contains only minor amounts of cadmium (Pettersson Grawe and Oskarsson 2000), it seems highly unlikely that an increased bone turnover would release significant amounts of cadmium.

This is the first study on cadmium-associated effects on bone in a population residing in an area with no known historical cadmium contamination, assuming a rather constant exposure over time. Nevertheless, our results are in accordance with findings of cadmium-associated effects on BMD and fractures in Swedes (of both sexes) with a similarly low present environmental exposure (Alfvén et al. 2000, 2004), Belgians with a somewhat higher exposure (Staessen et al. 1999), Japanese women (Honda et al. 2003), and Chinese men and women (Nordberg et al. 2002; Wang et al. 2003) with considerably higher exposure levels. In the present study, we obtained detailed information on several possible risk modifiers and confounders for osteoporosis, such as physical activity, menarche, menopausal status, and HRT. This enabled us to ascertain associations between low cadmium exposure and bone effects and our findings support a causal explanation.

The effect of cadmium on bone resorption in our study was even more pronounced after menopause (interaction), in accordance with results from animal (Bhattacharyya et al. 1988) and human studies (Staessen et al. 1999), and in line with the fact that those affected by the Itai-Itai disease were mainly women after menopause (Kjellström 1986).

Although the mechanism by which cadmium exerts effects on bone is far from clear, studies on humans have indicated an effect mediated through kidney damage (Alfvén et al. 2000; Horiguchi et al. 2005; Nordberg et al. 2002). We explored the mechanism by measuring markers of both bone metabolism and kidney effects. In contrast to previous reports, we suggest a direct effect of cadmium on bone resorption (osteoclasts), resulting in increased U-DPD. Such stimulation of bone resorption has been demonstrated in both animal and in vitro studies (Bhattacharyya et al. 1988; Brzoska and Moniuszko-Jakuniuk 2004, 2005; Carlsson and Lundholm 1996; Regnathan et al. 2003; Sacco-Gibson et al. 1992; Wilson et al. 1996). Because PTH is the main regulator of calcium metabolism, an increased bone resorption would lead to a compensatory decrease in PTH, which is in line with our results. The fact that we found no association between cadmium and bone formation (osteocalcin and bALP) may reflect a cadmium-induced uncoupling between bone resorption and formation (Uritu et al. 2000). In contrast, studies on patients with Itai-Itai showed increased levels of markers of bone formation compared with controls (Aoshima et al. 2003; Kido et al. 1991; Tsuritani et al. 1994), and studies of other subjects with cadmium-induced tubular damage showed increased PTH (Nogawa et al. 1984; Tsuritani et al. 1992). This may indicate other mechanisms are involved in subjects with severe kidney damage.

An indirect effect on bone due to cadmium-induced kidney damage (Alfvén et al. 2000; Kjellström 1992), via impaired activation of vitamin D (Kjellström 1992; Nogawa et al. 1987), and increased excretion of calcium and decreased bone formation has been proposed. However, we found no association between cadmium and urinary calcium (Åkesson et al. 2005) or markers of bone formation (osteocalcin and bALP). This would indicate that the kidney was not involved, although the associations between the effect on bone and some of the renal effect markers may indicate some kidney-mediated effect.

Even though BMD is likely to reflect the risk of forearm fractures, it may not be a good index of osteoporosis in other parts of the skeleton, although there was correlation, albeit weak, between BMD of the radius and the hip in 81 women of the WHILA cohort (data not shown). Evaluation of cadmium exposure in relation to BMD of other sites associated with increased fracture risk, such as hip and lumbar spine, is required.

Clearly, the overall role of cadmium in the etiology of osteoporosis is limited. The observed difference in BMD between high- and low-exposed individuals corresponded to that of a 6-year increase in age or an 11-kg lower body weight. However, in view of the high prevalence of this disease, even a minor contribution is important at the population level. Furthermore, because the main cadmium exposure is via foods considered healthful and because everyone has lifelong exposure, our findings in combination with the observed effects on kidney (Åkesson et al. 2005) emphasize the importance of activities to reduce cadmium pollution of the environment.

Table 3. Multiple linear regression models between bone-related markers and either urinary or blood cadmium.

| Dependent/independent variable | Urinary cadmium | Blood cadmium |
|-------------------------------|-----------------|---------------|
|                               | β               | 95% CI        | R²            | β               | 95% CI        | R²            |
| BMD (g/cm²)a                  | −0.011          | −0.022 to −0.0002 | 0.24          | −0.002          | −0.009 to 0.006 | 0.22          |
| Cadmium (µg/L)a               | 0.002           | 0.002 to 0.002  |               | 0.002           | 0.002 to 0.003  |               |
| Weight (kg)                   | −0.004          | −0.006 to −0.003 |               | −0.004          | −0.006 to −0.003 |               |
| Age (years)                   |                 |               |               |                 |               |               |
| Menopauseb                    | p < 0.001       |               |               | p < 0.001       |               |               |
| Seasonb                       | p = 0.018       |               |               | NS              |               |               |
| Menarche                      | NS              |               |               | NS              |               |               |
| PTH (ng/L)                    | −4.3            | −7.1 to −1.5   | 0.10          | −2.2            | −4.0 to −0.37  | 0.09          |
| Weight (kg)                   | 0.14            | 0.06 to 0.22   |               | 0.15            | 0.07 to 0.23   |               |
| Alcohol (g/week)              | −0.03           | −0.05 to −0.01 |               | −0.03           | −0.05 to −0.006 |               |
| Pack-years                    | p < 0.001       |               |               | NS              |               |               |
| bALP (µg/L)                   | 0.95            | −0.04 to 1.9   | 0.14          | NS              |               |               |
| Cadmium (µg/L)a               | p < 0.001       |               |               | NS              |               |               |
| Alcohol (g/week)              | NS              |               |               | NS              |               |               |
| Age                           | NS              |               |               | NS              |               |               |
| U-DPD (nmol/L)                | 17              | 14 to 21       | 0.12          | 1.8             | −0.7 to 4.4    | 0.03          |
| Cadmium (µg/L)a               | p < 0.001       |               |               | p < 0.001       |               |               |
| Menopauseb                    | p < 0.001       |               |               | NS              |               |               |
| Seasonb                       | NS              |               |               | NS              |               |               |
| Alcohol (g/week)              | NS              |               |               | NS              |               |               |

Abbreviations: CI, confidence interval; NS, not significant; R², explained adjusted variance for the total model.

*Adjusted to the mean urinary density. †Three categories for menopause (HRT, premenopause, and postmenopause) and three categories for season (summer, fall, and winter) were included in the models as fixed factors (p not estimated).

**Significant interactions: urinary cadmium and menopause (p = 0.022).
REFERENCES

Akesson A, Lundh T, Vahter M, Bjelland P, Lidfelt J, Nerbrand C, et al. 2005. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. Environ Health Perspect 113:1627–1631.

Alfvén T, Elander CG, Carlsson MD, Grubb A, Hellstrom L, Persson B, et al. 2000. Low-cadmium exposure and osteoporosis. J Bone Miner Res 15(3):1579–1586.

Alfvén T, Elander CG, Hellstrom L, Lagoarde, J Århoplu. 2004. Cadmium exposure and distal forearm fractures. J Bone Miner Res 19(3):900–905.

Aoshima K, Fan J, Cai Y, Kato T, Tanashi H, Kasumi M, 2000. Assessment of bone metabolism in cadmium-induced renal tubular dysfunction by measurements of biochemical markers. Toxicol Lett 130(3):183–192.

Barrany E, Bergdahl IA, Schutz A, Skerfving S, Oskarsson A. 1997. Inductively coupled plasma mass spectrometry for direct multi-element analysis of diluted human blood and serum. J Anal Atomic Spectrometry 12:1005–1009.

Berglund M, Akesson A, Bjelland P, Vahter M. 2000. Metal-bone interactions. Toxicol Lett 112:113-219–225.

Bhattacharyya MH, Whelon BD, Stern PH, Peterson DP. 1988. Cadmium accelerates bone loss in ovariectomized mice and fetal rat limb bones in culture. Proc Natl Acad Sci USA 85(22):8761–8765.

Brzoska MM, Moniuszko-Jakoniuk J. 2004. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats. Bone 35(5):1180–1191.

Bragoza MM, Moniuszko-Jakoniuk J. 2005. Disorders in bone metabolism of female rats chronically exposed to cadmium. Toxicol Appl Pharmacol 212:60–63.

Carlsson L, Lundholm CE. 1996. Characterisation of the effects of cadmium on the release of calcium and on the activity of some enzymes from neonatal mouse calvaria in culture. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 115(3):251–256.

Consensus Development Conference. 1993. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):486–560.

Garrido Latore F, Hernandez-Avila M, Tamayo Orozco J, Albores Medina CA, Aro A, Palazuelos E, et al. 2003. Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. Environ Health Perspect 111:631–636.

Genant HK, Cooper C, Poor Q, Reid I, Ehrlich G, Kanis J, et al. 1999. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10(4):259–264.

Honda R, Tsurtani I, Nishijo M, Aoshima K, Yasuda A, 2004. Serum bone-type alkaline phosphatase and C-terminal telopeptide of type I collagen in postmenopausal women. J Bone Miner Metab 22(8):424–428.

Ishizaki M, Genant HK, Cooper C, Poor Q, Reid I, Ehrlich G, Kanis J, et al. 1999. 1 alpha, 25-dihydroxyvitamin D level. Int Arch Occup Environ Health 72(3):205–211.

Jansson A, Ohlsson C, Lehto L, Jonson R, Ljunghall H, Marklund K, et al. 1999. Measurement of Bone Density (in Swedish). Stockholm.Swedish Council on Technology Assessment in Health Care.

Kanis JA, Johnell O, De Laet C, Jonsson B, D’Agostino RB, et al. 2000. Assessment of bone metabolism in women with low environmental cadmium exposure. J Bone Miner Res 15(7):1237–1244.

Kido T, Honda R, Tsurtani I, Ishizaki M, Yamada Y, Nagawa K, et al. 1991. Asessment of cadmium-induced osteopenia by measurement of serum bone Gla protein, parathyroid hormone, and 1 alpha,25-dihydroxyvitamin D. J Appl Toxicol 11(3):161–166.

Kjellstrom T. 1986. Itai-Itai disease. In: Cadmium and Health: A Toxicological and Epidemiological Appraisal. Vol II. Effects and Response (Friberg L, Elinder CG, Kjellstrom T, Nordberg G, eds). Boca Raton, FL:CRC Press, 257–290.

Kjellström T. 1992. Mechanism and epidemiology of bone effects of cadmium. In: Cadmium in the Human Environment: Toxicity and Carcinogenicity (Nordberg G, Alessio L, Herber R, eds). IARC Sci Publ 118:301–310.

Lidfeldt J, Nerbrand C, Samioce G, Schersten B, Agardh CD. 2001. A screening procedure detecting high-risk candidates for DGGT. The Women’s Health in the Lund Area (WHILA) study: a population based study of middle-aged women. Eur J Epidemiol 17(10):943–951.

Nash D, Magder LS, Shervin R, Rubin RJ, Silbergeld EK. 2004. Bone density-related predictors of bone lead level among peri- and postmenopausal women in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 160(9):901–911.

National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. 2001. Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795.

Nilsson U, Attewell R, Christoffersson JO, Schutz A, Ahlgren L, Ringertz H, Johansson C, Johnell O, Jonson R, Ljunghall S, Schersten B, Agardh CD, et al. 1986. Itai-itai disease. In: Cadmium and Health: A Toxicological and Epidemiological Appraisal. Vol II. Effects and Response (Friberg L, Elinder CG, Kjellstrom T, Nordberg G, eds). Boca Raton, FL:CRC Press, 257–290.

Nordberg G, Jin T, Bernard A, Florers S, Buchet JP, Ye T, et al. 2002. Low bone density and renal dysfunction following environmental cadmium exposure in China. Ambio 31(6):478–481.

Oleszczuk C, Pietrowiski JK, Subdys JK, Gross A. 1998. Urinary cadmium as indicator of renal cadmium in humans: an autopsy study. Hum Exp Toxicol 17(1):302–306.

Petersson Graeve K, Oskarsson A. 2000. Cadmium in milk and mammary gland in rats and mice. Arch Toxicol 73(10):1151-927–937.

Reganathan A, Glesna D, Wilson AK, Song J, Nicolaides F, Flores T, et al. 2003. Microarray analysis of changes in bone cell gene expression early after cadmium gavage in mice. Toxicol Appl Pharmacol 191(3):272–293.

Ringertz H, Johansson C, Johnell D, Jonson R, Ljunghall S, Marklund K, et al. 1995. Measurement of Bone Density (in Swedish). Stockholm.Swedish Council on Technology Assessment in Health Care.

Sacco-Gibson N, Chaufrday S, Brock A, Sickles AB, Patel B, Hegstad R, et al. 1992. Cadmium effects on bone metabolism: accelerated resorption in ovariectomized, aged beagles. Toxicol Appl Pharmacol 113(2):274–283.

Staessen JA, Roels HA, Emelianov O, Kuznetsova T, Thils L, Vrang, Vronskovai J, et al. 1999. Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study. Public Health and Environmental Exposure to Cadmium (PheoCad) Study Group. Lancet 353(9159):1140–1144.

Suwazono Y, Akesson A, Alfvén T, Järup L, Vahter M. 2000. Creatinine versus specific gravity-adjusted urinary cadmium concentrations. Biomarkers 10(2):117–126.

Tsurtani I, Honda R, Ishizaki M, Yamada Y, Aoshima K, Kasumi M. 1994. Serum bone-type alkaline phosphatase activity in women living in a cadmium-polluted area. Toxicol Lett 71(3):209–216.

Tsurtani I, Honda R, Ishizaki M, Yamada Y, Kido T, Nagawa K. 1992. Impairment of vitamin D metabolism due to environmental cadmium exposure, and possible relevance to sex-related differences in vulnerability to the bone damage. J Toxicol Environ Health 37(10):519–533.

Urio K, Morimoto I, Kato K, Okazaki Y, Okada Y, Qie YL, et al. 2000. Uncoupling between bone formation and resorption in ovariectomized rats with chronic cadmium exposure. Toxicol Appl Pharmacol 164(3):264–272.

Vahter M, Berglund M, Akesson A. 2004. Toxic metals and the menopause. J Br Mensa Soc 102(5):60–65.

Wang H, Zhu G, Shi Y, Weng S, Jia T, Kong Q, et al. 2003. Influence of environmental cadmium exposure on forearm bone density. J Bone Miner Res 18(3):553–560.

Webber CE, Chettle DR, Bowins RJ, Beaumont LF, Gordon CL, Song A, et al. 1995. Hormone replacement therapy may reduce the return of endogenous lead from bone to the circulation. Environ Health Perspect 103:1150–1153.

WHO. 1994. Assessment of Fracture Risk and Its Application to Screening of Postmenopausal Osteoporosis. Geneva:World Health Organization.

Wilson AK, Cerny EA, Smith BD, Wagh A, Bhattacharyya MH. 1996. Effects of cadmium on osteoclast formation and activity in vitro. Toxicol Appl Pharmacol 140(2):451–460.